文献速递肾移植

英夫利西单抗诱导治疗对 deceased donor 肾移植受者无效且增加 BK 病毒感染:CTOT-19 试验结果

Infliximab Induction Lacks Efficacy and Increases BK Virus Infection in Deceased Donor Kidney Transplant Recipients: Results of the CTOT-19 Trial.
PubMed 文献 · J Am Soc Nephrol · 2022-10-04

这项随机、双盲、安慰剂对照、15 中心 2 期试验纳入 225 例首次 deceased donor 肾移植受者,比较再灌注前给予英夫利西单抗 3 mg/kg 与生理盐水安慰剂对 24 个月 eGFR 的影响。两组 24 个月 eGFR 无差异,英夫利西单抗组需调整免疫抑制的 BK 病毒血症发生率更高(28.9% vs 13.4%,P=0.004),BK 病毒肾病有更高趋势(13.3% vs 4.9%,P=0.06)。

要点

  • 英夫利西单抗组与安慰剂组 24 个月 eGFR 无显著差异(52.45 vs 57.35 ml/min per 1.73 m²,P=0.1)。
  • 英夫利西单抗组需调整免疫抑制的 BK 病毒血症发生率高于安慰剂组(28.9% vs 13.4%,P=0.004)。
  • 英夫利西单抗组 BK 病毒肾病发生率有高于安慰剂组的趋势(13.3% vs 4.9%,P=0.06)。

核心结论

  • 在該免疫抑制方案下,英夫利西单抗诱导治疗对 deceased donor 肾移植受者无获益。
  • 干预意外增加 BK 病毒感染发生率,凸显以移植周围炎症为靶点改善肾移植结局的策略具有复杂性。

研究设计与样本

  • 随机、双盲、安慰剂对照、15 中心 2 期临床试验(CTOT-19,NCT02495077)。
  • 共 225 例首次 deceased donor 肾移植受者,38.2% 为 Black/African American,44% 为 White。
  • 随机接受再灌注前静脉英夫利西单抗 3 mg/kg 或生理盐水安慰剂。
  • 所有患者接受兔抗胸腺细胞球蛋白诱导,并以他克莫司、吗替麦考酚酯和泼尼松维持免疫抑制。

主要发现

  • 主要终点 24 个月 eGFR:英夫利西单抗组 52.45 ml/min per 1.73 m²(95%CI 48.38 至 56.52)vs 安慰剂组 57.35 ml/min per 1.73 m²(95%CI 53.18 至 61.52),P=0.1。
  • 两组在移植肾功能延迟恢复、活检证实的急性排斥反应、新生供者特异性抗体产生或移植物丢失/死亡方面无显著差异。
  • 两组免疫抑制无差异;移植后第 7 天血浆分析显示英夫利西单抗组 TNF 较安慰剂组低约十倍(P<0.001)。
  • 需调整免疫抑制的 BK 病毒血症在英夫利西单抗组更常见(28.9% vs 安慰剂组 13.4%,P=0.004)。
  • BK 病毒肾病在英夫利西单抗组有更高趋势(13.3% vs 安慰剂组 4.9%,P=0.06)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ischemia-reperfusion (IR) of a kidney transplant (KTx) upregulates TNF α production that amplifies allograft inflammation and may negatively affect transplant outcomes. METHODS: We tested the effects of blocking TNF peri-KTx via a randomized, double-blind, placebo-controlled, 15-center, phase 2 clinical trial. A total of 225 primary transplant recipients of deceased-donor kidneys (KTx; 38.2% Black/African American, 44% White) were randomized to receive intravenous infliximab (IFX) 3 mg/kg or saline placebo (PLBO) initiated before kidney reperfusion. All patients received rabbit anti-thymocyte globulin induction and maintenance immunosuppression (IS) with tacrolimus, mycophenolate mofetil, and prednisone. The primary end point was the difference between groups in mean 24-month eGFR. RESULTS: There was no difference in the primary end point of 24-month eGFR between IFX (52.45 ml/min per 1.73 m 2 ; 95% CI, 48.38 to 56.52) versus PLBO (57.35 ml/min per 1.73 m 2 ; 95% CI, 53.18 to 61.52; P =0.1). There were no significant differences between groups in rates of delayed graft function, biopsy-proven acute rejection (BPAR), development of de novo donor-specific antibodies, or graft loss/death. Immunosuppression did not differ, and day 7 post-KTx plasma analyses showed approximately ten-fold lower TNF ( P <0.001) in IFX versus PLBO. BK viremia requiring IS change occurred more frequently in IFX (28.9%) versus PLBO (13.4%; P =0.004), with a strong trend toward higher rates of BKV nephropathy in IFX (13.3%) versus PLBO (4.9%; P =0.06). CONCLUSIONS: IFX induction therapy does not benefit recipients of kidney transplants from deceased donors on this IS regimen. Because the intervention unexpectedly increased rates of BK virus infections, our findings underscore the complexities of targeting peritransplant inflammation as a strategy to improve KTx outcomes.Clinical Trial registry name and registration number:clinicaltrials.gov (NCT02495077).

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Hricik DE, Armstrong B, Alhamad T, et al. Infliximab Induction Lacks Efficacy and Increases BK Virus Infection in Deceased Donor Kidney Transplant Recipients: Results of the CTOT-19 Trial. J Am Soc Nephrol. 2022. PMID: 36195441. doi:10.1681/ASN.2022040454

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。